Edwards Lifesciences’ third-quarter results
Edwards Lifesciences (EW) is scheduled to announce its third-quarter earnings results after the market closes on October 23. The company is a leading player in the artificial heart valve market.
Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%. In the second quarter, Edwards Lifesciences reported sales of $0.97 billion, representing ~15.5% YoY growth. The company’s sales came in ahead of analysts’ estimates.
In the graph above, you can compare Edwards Lifesciences’ quarterly results with Wall Street’s estimates. Its peers Boston Scientific (BSX), Abbott Laboratories (ABT), and Thermo Fisher Scientific (TMO) are expected to report sales growth of 8.2%, 12%, and 11.5%, respectively, in their recently ended quarters.
Edwards Lifesciences expects to report strong sales in the third quarter of 2018 and in the whole of 2018. For the third quarter, the company expects to register sales in the range of $900 million–$950 million.
The company increased its 2018 guidance range during its second-quarter earnings release. It now expects to register 2018 sales at the high end of the $3.5 billion–$3.9 billion range. For its THVT (transcatheter heart valve therapy) segment, Edwards Lifesciences expects 2018 sales at the high end of the $2.1 billion–$2.4 billion range. For the SHVT (structural heart valve therapy) and Critical Care segments, the company expects to register sales at the high end of the $810 million–$850 million and $610 million–$650 million ranges, respectively.
In the next article, we’ll see what we can expect from Edwards Lifesciences’ EPS in the third quarter.